Tyra Biosciences (NASDAQ:TYRA) Director Gilla Kaplan Sells 14,295 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan sold 14,295 shares of the firm’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total transaction of $528,486.15. Following the completion of the transaction, the director owned 28,231 shares in the company, valued at $1,043,700.07. The trade was a 33.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Tyra Biosciences Stock Down 4.6%

TYRA opened at $36.29 on Friday. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $39.15. The company has a 50 day moving average of $32.90 and a two-hundred day moving average of $23.77. The company has a market cap of $1.95 billion, a P/E ratio of -18.05 and a beta of 1.06.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on TYRA. Piper Sandler boosted their price objective on Tyra Biosciences from $42.00 to $56.00 and gave the stock an “overweight” rating in a research note on Friday, March 20th. William Blair initiated coverage on Tyra Biosciences in a research note on Tuesday, February 10th. They issued an “outperform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, January 21st. Cantor Fitzgerald assumed coverage on Tyra Biosciences in a research report on Tuesday, February 24th. They set an “overweight” rating on the stock. Finally, Jefferies Financial Group upped their price target on Tyra Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.67.

Institutional Trading of Tyra Biosciences

Several large investors have recently modified their holdings of TYRA. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Tyra Biosciences by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after purchasing an additional 534 shares during the last quarter. AQR Capital Management LLC increased its holdings in Tyra Biosciences by 2.0% during the 4th quarter. AQR Capital Management LLC now owns 28,631 shares of the company’s stock worth $753,000 after purchasing an additional 562 shares during the last quarter. MetLife Investment Management LLC raised its position in shares of Tyra Biosciences by 5.0% in the 4th quarter. MetLife Investment Management LLC now owns 15,356 shares of the company’s stock valued at $404,000 after purchasing an additional 725 shares in the last quarter. Virtus Investment Advisers LLC raised its position in shares of Tyra Biosciences by 6.7% in the 4th quarter. Virtus Investment Advisers LLC now owns 11,756 shares of the company’s stock valued at $309,000 after purchasing an additional 741 shares in the last quarter. Finally, Deutsche Bank AG boosted its stake in shares of Tyra Biosciences by 5.8% during the 4th quarter. Deutsche Bank AG now owns 16,377 shares of the company’s stock valued at $431,000 after buying an additional 894 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.